Stockscreener 앱 받기
7.23
5.00%
-0.35
전일 마감가:
$7.58
열려 있는:
$7.4
하루 거래량:
303.45K
Relative Volume:
0.56
시가총액:
$205.15M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
-6.2328
EPS:
-1.16
순현금흐름:
$-21.00M
1주 성능:
-13.45%
1개월 성능:
+2.57%
6개월 성능:
-59.66%
1년 성능:
-55.14%
1일 변동 폭
$7.115
$7.54
1주일 범위
$6.79
$8.4766
52주 변동 폭
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.22 | 215.38M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.50 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.35 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.71 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.87 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
290.93 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics to Attend Upcoming Investor Conference - PharmiWeb.com
mRNA drug developer Arcturus set for Leerink healthcare fireside chat - Stock Titan
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript - Insider Monkey
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026 - Meyka
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative - simplywall.st
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Piper Sandler Lowers Price Target for Arcturus Therapeutics (ARC - GuruFocus
New nasal vaccine protects lungs for months against viruses, bacteria, and allergens - AOL.com
Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00 - MarketBeat
Arcturus Therapeutics reports financial results and pipeline progress - Traders Union
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcturus Q4 2025 misses expectations, stock drops - Investing.com South Africa
Arcturus Therapeutics Q4 Earnings Call Highlights - MarketBeat
ARCTURUS THERAPEUTICS ($ARCT) Releases Q4 2025 Earnings - Quiver Quantitative
Arcturus (ARCT) Faces Shortfall in Q4 Revenue, Focuses on New Th - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates By Investing.com - Investing.com Canada
Arcturus Therapeutics (NASDAQ:ARCT) Releases Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates - Investing.com India
Arcturus Therapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arcturus Therapeutics falls 5% on weak quarterly revenue By Investing.com - Investing.com Nigeria
Arcturus Therapeutics falls 5% on weak quarterly revenue - Investing.com South Africa
Arcturus Therapeutics 10-K: Revenue $82.0M; EPS not reported - TradingView
KOSTAIVE setback and mRNA pipeline progress at Arcturus (NASDAQ: ARCT) - Stock Titan
Arcturus Therapeutics (ARCT) trims 2025 loss and extends cash runway into Q2 2028 - Stock Titan
Arcturus Therapeutics Q4 Earnings Assessment - Benzinga
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress - Yahoo Finance
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings - GuruFocus
Earnings Preview: Arcturus Therapeutics - Sahm
Momentum Shift: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn
Bethany Children's Health Center unveils immersive experience plans - AOL.com
Arcturus Therapeutics Holdings Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Arcturus Therapeutics (ARCT) Stock Analysis: Exploring a 304% Potential Upside Amidst Clinical Pipeline Advances - DirectorsTalk Interviews
Arcturus Therapeutics (ARCT) Expected to Post Earnings on Tuesday - MarketBeat
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Potential 346% Upside with Innovative mRNA Therapies - DirectorsTalk Interviews
Technical Reactions to ARCT Trends in Macro Strategies - Stock Traders Daily
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Volatility Watch: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesMarket Growth Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 - BioSpace
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Co - PharmiWeb.com
Balyasny reports no Arcturus Therapeutics (ARCT) stake in amended 13G/A - Stock Titan
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating - MSN
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Arcturus cut to Neutral at Citi on data for mRNA candidate - MSN
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.02%
자본화:
|
볼륨(24시간):